肺炎球菌结合疫苗接种对冈比亚肺炎球菌鼻咽携带的影响:基于人群的横断面调查
在冈比亚2009年、2015年和2017年开展年龄分层的人群横断面鼻咽携带调查,评估PCV7(2009年8月引入)和PCV13(2011年5月替换)对疫苗型肺炎球菌携带的影响。0-4岁儿童疫苗型携带率从2009年的42.6%降至2015年的14.9%和2017年的17.5%,各年龄组非疫苗型携带均增加。
要点
- 0-4岁儿童疫苗型携带率从2009年42.6%降至2015年14.9%、2017年17.5%。
- 5-14岁儿童疫苗型携带率2017年较2009年调整患病率比为0.70。
- 所有年龄组非疫苗型肺炎球菌携带均增加,残留血清型包括34、15B、3、16F等。
核心结论
- 引入PCV与幼儿及年长儿童疫苗型肺炎球菌携带减少相关,但残留携带率仍较高。
- 持续存在的疫苗型和非疫苗型携带表明人群中肺炎球菌传播持续且显著。
研究设计与样本
- 在冈比亚开展2009年、2015年和2017年三次年龄分层、基于人群的横断面携带调查。
- 2009年8月引入七价PCV(PCV7),无补种,接种程序为2、3、4月龄;2011年5月替换为PCV13。
- 鼻咽标本按WHO指南采集和处理,计算PCV引入前后疫苗型携带的观察和调整患病率比(PR)。
- 三次调查分别入组2988、3162和2709名参与者。
主要发现
- 0-4岁儿童疫苗型携带率2009年为42.6%,2015年降至14.9%,2017年为17.5%;2015年vs 2009年调整PR 0.32(95%CI 0.27,0.38),2017年vs 2009年调整PR 0.38(95%CI 0.31,0.46)。
- 5-14岁儿童疫苗型携带率三次调查分别为16.6%、15.1%和15.8%;2017年vs 2009年调整PR 0.70(95%CI 0.58,0.83)。
- 15-44岁人群疫苗型携带率三次调查分别为6.4%、5.7%和7.1%;2017年vs 2009年调整PR 0.59(95%CI 0.46,0.75)。
- ≥45岁人群疫苗型携带率三次调查分别为4.5%、6.5%和4.5%。
- 所有年龄组非疫苗型携带均增加;常见残留血清型为0-4岁34和15B、5-14岁3和34、≥15岁3和16F。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The introduction of pneumococcal conjugate vaccines (PCV) has reduced carriage of vaccine-type (VT) pneumococci in many settings. We determined the impact of The Gambia's national PCV programme on carriage of VT pneumococci in the population. METHODS: Seven-valent PCV (PCV7) was introduced in August 2009 without catch-up and with doses scheduled at 2, 3, 4 months of age; it was replaced by PCV13 in May 2011. We did cross-sectional carriage surveys in 2009, 2015, and 2017 in age-stratified, population-based samples. Nasopharyngeal specimens were collected and processed according to WHO guidelines. We calculated observed and adjusted prevalence ratios (PR) of VT carriage before and after PCV introduction. FINDINGS: We enrolled 2988, 3162, and 2709 participants in 2009, 2015, and 2017 respectively. The baseline (2009) prevalence of VT pneumococcal carriage among children aged 0-4 years was 42.6 %, which declined to 14.9 % and 17.5 % in 2015 and 2017 respectively (adjPR 0.32 [95 % CI 0.27, 0.38] and 0.38 [0.31, 0.46] respectively). VT prevalence among children aged 5-14 years was 16.6 %, 15.1 %, and 15.8 % in the three surveys (2017 vs 2009, adjPR 0.70 [0.58, 0.83]). VT prevalence among 15-44 year-olds was 6.4 %, 5.7 %, and 7.1 % in the three surveys (2017 vs 2009, adjPR 0.59 [0.46, 0.75]), while in those aged ≥ 45 years it was 4.5 %, 6.5 %, and 4.5 % respectively. Non-VT carriage increased in all age-groups. Prevalent residual serotypes were 34 and 15B (age 0-4 years), 3 and 34 (age 5-14 years), and 3 and 16F (age ≥ 15 years). CONCLUSIONS: Introduction of PCV was associated with reduced VT pneumococcal carriage in young, and older children, although with substantial residual prevalence. Persisting VT, and non-VT, carriage indicate significant, persistent transmission of pneumococci in the population.
引用
- Mackenzie GA, Hossain I, Salaudeen R, et al. Impact of pneumococcal conjugate vaccination on pneumococcal nasopharyngeal carriage in the Gambia: Population-based cross-sectional surveys. Vaccine. 2024. PMID: 38490820. doi:10.1016/j.vaccine.2024.02.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。